@deluciavitality's testosterone optimization claims, checked

What did @deluciavitality actually say?

The transcript captured from this video is largely inaudible or garbled, which makes it impossible to fact-check specific spoken claims with confidence. What we can work with is the caption, which makes a clear and specific argument: men on TRT who achieve total testosterone levels of 1,800 to 2,000 ng/dL are misreading those numbers as success. The creator frames this as a common clinical pattern, writing "I see this all the time" and suggesting "your body is not impressed by extreme numbers." That is a real clinical debate, and it is worth unpacking honestly.

Because the actual spoken transcript is unintelligible, this fact-check is based primarily on the written caption and the stated clinical claims within it. We will not put words in the creator's mouth that we cannot verify from the audio.

Does the science back this up?

On the core point, yes, mostly. Supraphysiologic testosterone levels during TRT are associated with real clinical risks, and chasing a high total testosterone number is not the same as optimizing hormonal health. The claim holds up, though the framing oversimplifies the picture.

The American Urological Association guidelines recommend maintaining total testosterone levels within the physiologic range, generally 400 to 700 ng/dL for most men, though some clinicians use a broader target. Levels consistently above 1,500 ng/dL are considered supraphysiologic. Research published by Ohlander et al. (2018, Urology) documented that elevated hematocrit, erythrocytosis, and cardiovascular strain are real concerns at persistently high testosterone levels. Separately, Calof et al. (2005, Journals of Gerontology) found dose-dependent increases in adverse events including polycythemia and edema at higher testosterone doses. The caption's implicit argument, that more is not always better, is supported by these findings.

Where it gets more complicated: some men with certain metabolic profiles or high SHBG do require higher total testosterone to achieve adequate free testosterone. Total testosterone alone is an incomplete metric.

What did they get wrong (or right)?

The creator gets the general principle right. Supraphysiologic testosterone is not a goal to celebrate, and treating a lab number as a trophy is a genuine problem in the TRT optimization space. That part deserves credit.

What is missing, and what edges this toward oversimplification, is any acknowledgment of free testosterone and sex hormone-binding globulin (SHBG). A man with high SHBG could have a total testosterone of 1,800 ng/dL and still have low free testosterone, which is the biologically active fraction. Conversely, a man with low SHBG might have significant free testosterone at levels that look moderate on paper. Morgentaler and Traish (2009, European Urology) have written extensively on why free testosterone is the more clinically relevant measure in many cases.

The caption also implies a universal ceiling without specifying one, which leaves the audience with vague anxiety about high numbers rather than actionable understanding. Saying "your body is not impressed by extreme numbers" is memorable but does not help someone understand what range is actually appropriate for their clinical situation.

What should you actually know?

Total testosterone is one data point, not the full story. If you are on TRT and your provider is only tracking total testosterone, that is worth asking about. Free testosterone, SHBG, hematocrit, estradiol, and symptom response are all part of a complete clinical picture.

The Endocrine Society's 2018 clinical practice guidelines recommend targeting mid-normal physiologic ranges for total testosterone during TRT, typically 400 to 700 ng/dL, while monitoring for adverse effects including erythrocytosis, which is an increase in red blood cell mass. Persistently supraphysiologic levels are associated with increased cardiovascular risk in some populations, though the long-term data on TRT safety overall remains an active area of research. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found no significant increase in major cardiovascular events with TRT in men with hypogonadism and preexisting cardiovascular risk, but that study used doses designed to maintain physiologic levels, not supraphysiologic ones.

If you are managing your own TRT or discussing it with a provider, the conversation should center on symptoms, free testosterone, hematocrit, and cardiovascular risk factors, not on how high a number you can hit.